Celgene Shares Outstanding 2006-2019 | CELG

Celgene shares outstanding history from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Celgene shares outstanding for the quarter ending March 31, 2019 were 0.721B, a 6.22% decline year-over-year.
  • Celgene 2018 shares outstanding were 0.734B, a 9.26% decline from 2017.
  • Celgene 2017 shares outstanding were 0.809B, a 0.67% increase from 2016.
  • Celgene 2016 shares outstanding were 0.803B, a 2.62% decline from 2015.
Celgene Annual Shares Outstanding
(Millions of Shares)
2018 734
2017 809
2016 803
2015 825
2014 836
2013 861
2012 882
2011 925
2010 939
2009 935
2008 885
2007 864
2006 814
2005 781
Celgene Quarterly Shares Outstanding
(Millions of Shares)
Q1 2019 721
Q4 2018 734
Q3 2018 720
Q2 2018 733
Q1 2018 768
Q4 2017 809
Q3 2017 815
Q2 2017 812
Q1 2017 811
Q4 2016 803
Q3 2016 802
Q2 2016 802
Q1 2016 808
Q4 2015 825
Q3 2015 791
Q2 2015 825
Q1 2015 834
Q4 2014 836
Q3 2014 833
Q2 2014 831
Q1 2014 845
Q4 2013 861
Q3 2013 858
Q2 2013 859
Q1 2013 864
Q4 2012 882
Q3 2012 873
Q2 2012 891
Q1 2012 897
Q4 2011 925
Q3 2011 919
Q2 2011 940
Q1 2011 944
Q4 2010 939
Q3 2010 933
Q2 2010 935
Q1 2010 935
Q4 2009 935
Q3 2009 934
Q2 2009 934
Q1 2009 936
Q4 2008 885
Q3 2008 938
Q2 2008 933
Q1 2008 825
Q4 2007 864
Q3 2007 866
Q2 2007 863
Q1 2007 859
Q4 2006 814
Q3 2006 810
Q2 2006 741
Q1 2006 801
Q4 2005 781
Q3 2005 719
Q2 2005 704
Q1 2005 764
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $64.087B $15.281B
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $107.995B 12.21
Gilead Sciences (GILD) United States $85.316B 10.36
Vertex Pharmaceuticals (VRTX) United States $45.369B 54.84
Illumina (ILMN) United States $44.526B 51.60
Biogen (BIIB) United States $44.487B 8.44
CSL (CSLLY) Australia $35.586B 0.00
Regeneron Pharmaceuticals (REGN) United States $32.719B 15.38
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.673B 15.66
Incyte (INCY) United States $17.204B 69.76
Exact Sciences (EXAS) United States $15.024B 0.00
BioMarin Pharmaceutical (BMRN) United States $14.768B 0.00
SINO PHARMACEUT (SBMFF) China $14.154B 0.00
Seattle Genetics (SGEN) United States $12.157B 0.00
Sarepta Therapeutics (SRPT) United States $11.420B 0.00
Genmab (GNMSF) Denmark $11.291B 57.40
Array BioPharma (ARRY) United States $10.322B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $8.926B 29.32
Galapagos (GLPG) Belgium $8.704B 0.00
Guardant Health (GH) United States $8.043B 0.00
Bio-Techne Corp (TECH) United States $7.954B 54.27
Alnylam Pharmaceuticals (ALNY) United States $7.743B 0.00
Bluebird Bio (BLUE) United States $7.687B 0.00
Amarin (AMRN) Ireland $6.968B 0.00
Exelixis (EXEL) United States $6.551B 16.70
BeiGene (BGNE) Cayman Islands $5.653B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.786B 0.00
Ascendis Pharma (ASND) Denmark $4.751B 0.00
Blueprint Medicines (BPMC) United States $4.706B 0.00
Moderna (MRNA) United States $4.616B 0.00
Horizon Pharma Public (HZNP) Ireland $4.491B 11.57
Repligen (RGEN) United States $4.118B 102.59
Spark Therapeutics (ONCE) United States $3.727B 0.00
Mirati Therapeutics (MRTX) United States $3.724B 0.00
ACADIA Pharmaceuticals (ACAD) United States $3.686B 0.00
China Biologic Products (CBPO) China $3.670B 23.31
Alkermes (ALKS) Ireland $3.623B 0.00
MorphoSys AG (MOR) Germany $3.446B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.416B 0.00
Arena Pharmaceuticals (ARNA) United States $3.040B 6.18
Amicus Therapeutics (FOLD) United States $2.924B 0.00
Immunomedics (IMMU) United States $2.871B 0.00
UniQure (QURE) Netherlands $2.738B 0.00
Medicines (MDCO) United States $2.704B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.605B 0.00
Reata Pharmaceuticals (RETA) United States $2.529B 0.00
Halozyme Therapeutics (HALO) United States $2.439B 0.00
MyoKardia (MYOK) United States $2.295B 0.00
NeoGenomics (NEO) United States $2.282B 149.38
Nabriva Therapeutics AG (NBRV) Ireland $2.260B 0.00
Ligand Pharmaceuticals (LGND) United States $2.210B 18.31
Acceleron Pharma (XLRN) United States $2.199B 0.00
Emergent Biosolutions (EBS) United States $2.180B 18.93
Zai Lab (ZLAB) China $2.109B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.078B 0.00
Akcea Therapeutics (AKCA) United States $2.063B 0.00
Genomic Health (GHDX) United States $2.044B 43.42
Myriad Genetics (MYGN) United States $1.930B 19.20
Denali Therapeutics (DNLI) United States $1.917B 0.00
REGENXBIO (RGNX) United States $1.749B 0.00
Insmed (INSM) United States $1.672B 0.00
Cambrex (CBM) United States $1.510B 19.10
AnaptysBio (ANAB) United States $1.457B 0.00
Fate Therapeutics (FATE) United States $1.451B 0.00
RA PHARMCTL INC (RARX) United States $1.379B 0.00
Innoviva (INVA) United States $1.365B 3.78
Sangamo Therapeutics (SGMO) United States $1.364B 0.00
Athenex (ATNX) United States $1.286B 0.00
Alector (ALEC) United States $1.256B 0.00
Coherus BioSciences (CHRS) United States $1.233B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.187B 0.00
Editas Medicine (EDIT) United States $1.184B 0.00
Epizyme (EPZM) United States $1.142B 0.00
Cara Therapeutics (CARA) United States $1.070B 0.00
Dicerna Pharmaceuticals (DRNA) United States $1.023B 0.00
Codexis (CDXS) United States $1.022B 0.00
Twist Bioscience (TWST) United States $0.978B 0.00
Adverum Biotechnologies (ADVM) United States $0.978B 0.00
Principia Biopharma (PRNB) United States $0.974B 0.00
ANI Pharmaceuticals (ANIP) United States $0.973B 17.26
Momenta Pharmaceuticals (MNTA) United States $0.959B 0.00
Zymeworks (ZYME) Canada $0.940B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.924B 0.00
WAVE Life Sciences (WVE) Singapore $0.907B 0.00
Retrophin (RTRX) United States $0.879B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.866B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Vericel (VCEL) United States $0.853B 0.00
Arvinas (ARVN) United States $0.772B 0.00
Intellia Therapeutics (NTLA) United States $0.763B 0.00
Precision BioSciences (DTIL) United States $0.746B 0.00
Vanda Pharmaceuticals (VNDA) United States $0.704B 33.22
Zealand Pharma (ZEAL) Denmark $0.704B 8.22
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Cytokineticsorporated (CYTK) United States $0.670B 0.00
Clovis Oncology (CLVS) United States $0.654B 0.00
Intra-Cellular Therapies (ITCI) United States $0.643B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.639B 0.00
Cellectis S.A (CLLS) France $0.635B 0.00
Heska (HSKA) United States $0.622B 63.73
DBV Technologies S.A (DBVT) France $0.596B 0.00
Anika Therapeutics (ANIK) United States $0.581B 19.84
Stemline Therapeutics (STML) United States $0.580B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.569B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.560B 0.00
Revance Therapeutics (RVNC) United States $0.557B 0.00
CytomX Therapeutics (CTMX) United States $0.549B 0.00
MiMedx (MDXG) United States $0.525B 0.00
Pharming Group (PHGUF) Netherlands $0.521B 0.00
Mesoblast (MESO) Australia $0.494B 0.00
PHARMA MAR SA (PHMMF) Spain $0.453B 0.00
UROGEN PHARMA (URGN) United States $0.445B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.442B 0.00
Puma Biotechnology (PBYI) United States $0.405B 0.00
AC Immune SA (ACIU) Switzerland $0.398B 25.61
Prothena (PRTA) Ireland $0.389B 0.00
PDL BioPharma (PDLI) United States $0.379B 9.06
Arcus Biosciences (RCUS) United States $0.376B 0.00
Gritstone Oncology (GRTS) United States $0.372B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
Biofrontera AG (BFRA) Germany $0.369B 0.00
Scholar Rock Holding (SRRK) United States $0.361B 0.00
Bellus Health (BLUSF) Canada $0.361B 0.00
Albireo Pharma (ALBO) United States $0.354B 0.00
Merus (MRUS) Netherlands $0.352B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.351B 0.00
Prometic Life Sciences (PFSCD) Canada $0.349B 0.00
BioDelivery Sciences (BDSI) United States $0.348B 0.00
Avid Bioservices (CDMO) United States $0.347B 0.00
Kadmon Holdings (KDMN) United States $0.344B 0.00
Starpharma Holdings (SPHRY) Australia $0.343B 0.00
Agenus (AGEN) United States $0.340B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.333B 0.00
Acorda Therapeutics (ACOR) United States $0.332B 5.85
Senesco Technologies (ELOX) United States $0.331B 0.00
Theratechnologies (THERF) Canada $0.330B 0.00
Syros Pharmaceuticals (SYRS) United States $0.322B 0.00
Protagonist Therapeutics (PTGX) United States $0.310B 0.00
Sorrento Therapeutics (SRNE) United States $0.307B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.292B 0.00
Cellular Biomedicine (CBMG) United States $0.275B 0.00
Kindred Biosciences (KIN) United States $0.269B 0.00
Inovio Pharmaceuticals (INO) United States $0.266B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.261B 0.00
Sutro Biopharma (STRO) United States $0.253B 0.00
ChromaDex (CDXC) United States $0.253B 0.00
PHASEBIO PHARMA (PHAS) United States $0.249B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.248B 0.00
Dynavax Technologies (DVAX) United States $0.247B 0.00
Kamada (KMDA) Israel $0.241B 9.36
Athersys (ATHX) United States $0.235B 0.00
ADMA Biologics Inc (ADMA) United States $0.232B 0.00
Geron (GERN) United States $0.231B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.222B 0.00
Cel-Sci (CVM) United States $0.214B 0.00
CorMedix Inc (CRMD) United States $0.214B 0.00
Palatin Technologies (PTN) United States $0.211B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.206B 0.00
Cerecor (CERC) United States $0.199B 0.00
Five Prime Therapeutics (FPRX) United States $0.198B 0.00
Synlogic (SYBX) United States $0.196B 0.00
MannKind (MNKD) United States $0.195B 0.00
Abeona Therapeutics (ABEO) United States $0.193B 0.00
Mersana Therapeutics (MRSN) United States $0.191B 0.00
Affimed (AFMD) Germany $0.190B 0.00
Pfenex (PFNX) United States $0.187B 0.00
OSMOTICA PHARM (OSMT) United States $0.185B 0.00
Spero Therapeutics (SPRO) United States $0.185B 0.00
POXEL SA FRANCE (PXXLF) $0.184B 0.00
Compugen (CGEN) Israel $0.183B 0.00
Arsanis (XFOR) United States $0.180B 0.00
Enzo Biochem (ENZ) United States $0.179B 0.00
BioTime (BTX) United States $0.169B 11.30
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
Nicox SA (NICXF) France $0.162B 0.00
XOMA (XOMA) United States $0.159B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.158B 0.00
Strongbridge Biopharma (SBBP) United States $0.157B 9.03
Cue Biopharma (CUE) United States $0.151B 0.00
Liquidia Technologies (LQDA) United States $0.144B 0.00
OvaScience (MLND) United States $0.142B 0.00
TOCAGEN INC (TOCA) United States $0.141B 0.00
Adocia (ADOCY) France $0.140B 0.00
Celyad SA (CYAD) Belgium $0.139B 0.00
Northwest Biotherapeutics (NWBO) United States $0.134B 0.00
Dyadic (DYAI) United States $0.133B 0.00
Seres Therapeutics (MCRB) United States $0.128B 0.00
NantKwest (NK) United States $0.125B 0.00
Aptinyx (APTX) United States $0.123B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.122B 0.00
Alcobra (ARCT) United States $0.119B 0.00
Aduro Biotech (ADRO) United States $0.118B 0.00
Arbutus Biopharma (ABUS) Canada $0.115B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.112B 0.00
Verastem (VSTM) United States $0.110B 0.00
Checkpoint Therapeutics (CKPT) United States $0.110B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.109B 0.00
Menlo Therapeutics (MNLO) United States $0.108B 0.00
Novavax (NVAX) United States $0.107B 0.00
SESEN BIO, INC (SESN) United States $0.101B 0.00
Catalyst Biosciences (CBIO) United States $0.101B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.101B 0.00
Trevena (TRVN) United States $0.095B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.094B 0.00
Fortress Biotech (FBIO) United States $0.089B 0.00
Pluristem Therapeutics (PSTI) Israel $0.089B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.085B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.084B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.084B 0.00
Unum Therapeutics (UMRX) United States $0.079B 0.00
Selecta Biosciences (SELB) United States $0.078B 0.00
Curis (CRIS) United States $0.078B 0.00
AquaBounty Technologies (AQB) United States $0.076B 0.00
VBI Vaccines (VBIV) United States $0.076B 0.00
VTv Therapeutics (VTVT) United States $0.075B 0.00
Idera Pharmaceuticals (IDRA) United States $0.073B 0.00
Orgenesis (ORGS) United States $0.073B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.072B 0.00
Applied Genetic Technologies (AGTC) United States $0.071B 38.80
Signal Genetics (MGEN) United States $0.070B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.065B 0.00
Organovo Holdings (ONVO) United States $0.064B 0.00
ARAVIVE, INC (ARAV) United States $0.063B 0.00
Alimera Sciences (ALIM) United States $0.061B 0.00
Antibe Therapeutics (ATBPF) Canada $0.060B 0.00
Protalix BioTherapeutics (PLX) Israel $0.059B 0.00
Prima BioMed (IMMP) Australia $0.059B 0.00
Invo BioScience (IVOB) United States $0.055B 0.00
NewLink Genetics (NLNK) United States $0.054B 0.00
Oncobiologics (OTLK) United States $0.051B 0.00